FDG PET/CT参数与肿瘤吸收剂量在177Lu-lilotomab satetraxetan治疗复发非霍奇金淋巴瘤1期试验中的相关性
结果显示肿瘤吸收剂量范围为35-859 cGy,基线至3个月PET参数平均下降ΔSUVmax 61%、ΔMTV 80%、ΔTLG 77%,但未发现肿瘤吸收剂量与FDG PET或ceCT参数变化之间存在整体相关性,代谢应答者与非应答者间肿瘤吸收剂量也无显著差异。
要点
- 肿瘤吸收剂量范围为35-859 cGy,存在患者内和患者间变异。
- 基线至3个月PET参数平均下降:ΔSUVmax 61%、ΔMTV 80%、ΔTLG 77%。
- 未发现肿瘤吸收剂量与FDG PET或ceCT参数变化的相关性。
核心结论
- 分析未显示肿瘤吸收剂量与FDG PET或ceCT参数变化之间存在相关性。
- 包含冷抗体的联合方案可能是阻碍这种相关性的因素之一。
- 大多数患者中观察到患者内应答随肿瘤吸收剂量增加而增加,提示辐射敏感性或生物学存在个体差异。
研究设计与样本
- 患者接受不同预处理和预给药方案。
- 剂量学基于多次SPECT/CT图像进行。
- FDG PET/CT在基线及3个月和6个月进行。
- 基于Deauville标准在3个月和6个月评估病灶应答,基于ceCT在基线及6个月和12个月通过垂直径和(SPD)评估解剖变化。
主要发现
- 肿瘤吸收剂量范围为35至859 cGy。
- 观察到患者内和患者间变异。
- 基线至3个月PET参数平均下降:ΔSUVmax-3months 61%、ΔMTV3months 80%、ΔTLG3months 77%。
- 在病灶水平未发现肿瘤吸收剂量与FDG PET或ceCT参数变化之间的整体相关性。
- 代谢应答者与非应答者治疗后肿瘤吸收剂量无显著差异。
关键数值与推荐
- 病灶应答基于Deauville标准在3个月和6个月评估。
- 解剖变化通过ceCT的垂直径和(SPD)在基线及6个月和12个月评估。
临床怎么用
- 放射免疫治疗后FDG PET/CT参数变化与肿瘤吸收剂量无整体相关性,应答评估需结合多因素。
- 患者内应答随肿瘤吸收剂量增加而增加,提示需考虑个体化辐射敏感性。
局限性
- 包含冷抗体的联合方案可能影响剂量-效应相关性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: 177Lu-lilotomab satetraxetan targets the CD37 antigen and has been investigated in a first-in-human phase 1/2a study for relapsed non-Hodgkin lymphoma (NHL). Tumor dosimetry and response evaluation can be challenging after radioimmunotherapy (RIT). Changes in FDG PET/CT parameters after RIT and correlations with tumor-absorbed doses has not been examined previously in patients with lymphoma. Treatment-induced changes were measured at FDG PET/CT and ceCT to evaluate response at the lesion level after treatment, and correlations with tumor-absorbed doses were investigated. METHODS: Forty-five tumors in 16 patients, with different pre-treatment and pre-dosing regimens, were included. Dosimetry was performed based on multiple SPECT/CT images. FDG PET/CT was performed at baseline and at 3 and 6 months. SUVmax, MTV, TLG, and changes in these parameters were calculated for each tumor. Lesion response was evaluated at 3 and 6 months (PET3months and PET6months) based on Deauville criteria. Anatomical changes based on ceCT at baseline and at 6 and 12 months were investigated by the sum of perpendiculars (SPD). RESULTS: Tumor-absorbed doses ranged from 35 to 859 cGy. Intra- and interpatient variations were observed. Mean decreases in PET parameters from baseline to 3 months were ΔSUVmax-3months 61%, ΔMTV3months 80%, and ΔTLG3months 77%. There was no overall correlation between tumor-absorbed dose and change in FDG PET or ceCT parameters at the lesion level or significant difference in tumor-absorbed doses between metabolic responders and non-responders after treatment. CONCLUSION: Our analysis does not show any correlation between tumor-absorbed doses and changes in FDG PET or ceCT parameters for the included lesions. The combination regimen, including cold antibodies, may be one of the factors precluding such a correlation. Increased intra-patient response with increased tumor-absorbed doses was observed for most patients, implying individual variations in radiation sensitivity or biology. TRIAL REGISTRATION: ClinicalTrials.gov Identifier (NCT01796171). Registered December 2012.
引用
- Løndalen A, Blakkisrud J, Revheim ME, et al. FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2020. PMID: 33196921. doi:10.1007/s00259-020-05098-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。